What are the risks of fluoroquinolone use in patients younger than 18 years?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Fluoroquinolone Risks in Patients Under 18 Years

Fluoroquinolones should be restricted in children under 18 years to situations where no safe and effective alternative exists for treating multidrug-resistant infections, or when parenteral therapy is not feasible and no other effective oral agent is available 1.

Primary Safety Concerns

Musculoskeletal Toxicity

The most significant concern limiting fluoroquinolone use in children is arthrotoxicity, which causes irreversible joint damage in juvenile animals 1. In human pediatric patients, the clinical picture is more reassuring but not without risk:

  • Musculoskeletal adverse events occur in 9.3% of children receiving ciprofloxacin versus 6.0% in controls within 6 weeks of treatment 1
  • Most events are moderate intensity and transient 1
  • A 2022 meta-analysis found the overall incidence of musculoskeletal adverse events was only 0.76%, with a relative risk of 2.03 compared to controls 2
  • Adolescents aged 13-18 years appear most sensitive to musculoskeletal toxicity (RR 2.69) 2
  • Risk appears highest during 2-6 months follow-up (RR 2.56) 2

Critical caveat: While no sustained joint injury has been definitively documented in children, the possibility of rare occurrence cannot be excluded 1.

Other Serious Adverse Events

Beyond musculoskeletal concerns, fluoroquinolones carry multiple potentially life-threatening risks 1:

  • Central nervous system disorders (seizures, confusion)
  • QT interval prolongation with risk of torsades de pointes (potentially lethal arrhythmia)
  • Hepatic dysfunction
  • Disorders of glucose homeostasis (hypo/hyperglycemia)
  • Photosensitivity reactions
  • Gastrointestinal reactions (most common at 2.02% incidence) 2

Antimicrobial Resistance

The inappropriate use of fluoroquinolones drives bacterial resistance, a critical public health concern 1. This resistance pattern mirrors what occurred in adults and threatens the utility of these agents for future serious infections.

FDA-Approved Indications (Under 18 Years)

Only three indications are FDA-licensed for pediatric use 1:

  1. Complicated urinary tract infections and pyelonephritis (E. coli) in patients 1-17 years
  2. Postexposure treatment for inhalation anthrax
  3. Topical fluoroquinolones for conjunctivitis (>12 months) and acute otitis externa 3

Appropriate Off-Label Uses (When Justified)

Fluoroquinolones may be considered when both conditions are met 1:

  1. Infection caused by multidrug-resistant pathogens with no safe alternative
  2. Parenteral therapy not feasible and no other effective oral agent available

Specific clinical scenarios where use may be justified 1:

  • Pseudomonas aeruginosa infections: Chronic suppurative otitis media, malignant otitis externa, osteomyelitis/osteochondritis
  • Cystic fibrosis exacerbations: P. aeruginosa colonization requiring ambulatory treatment
  • Multidrug-resistant gastrointestinal infections: Shigella, Salmonella, Vibrio cholerae, Campylobacter jejuni
  • Mycobacterial infections: When isolates are fluoroquinolone-susceptible
  • Immunocompromised patients: Gram-negative infections requiring oral therapy with resistance to alternatives
  • Life-threatening allergies: When patient has documented severe allergy to all alternative agents

Agent-Specific Considerations

Levofloxacin may carry higher musculoskeletal risk (RR 1.33) compared to other fluoroquinolones 2. Consider ciprofloxacin as first choice when fluoroquinolone use is necessary.

Risk Mitigation Strategy

When fluoroquinolone use is deemed necessary:

  • Limit duration to shortest effective course
  • Avoid in adolescents 13-18 years when possible (highest musculoskeletal sensitivity) 2
  • Screen for risk factors: Concurrent corticosteroid use, renal disease, family history of QT prolongation
  • Monitor closely during treatment and for 2-6 months post-treatment (peak risk period) 2
  • Document justification clearly: specify why alternatives are inadequate
  • Culture-directed therapy: Use only when susceptibility confirmed or strongly suspected

Bottom Line

The overall adverse event rate of 5.39% in children using fluoroquinolones 2 is not negligible. While musculoskeletal events appear largely reversible, the combination of safety concerns and resistance implications mandates strict adherence to appropriate use criteria. Reserve fluoroquinolones for situations where the benefit clearly outweighs risk—primarily multidrug-resistant infections without safer alternatives.

References

Related Questions

Does repeated stopping and restarting of fluoroquinolone antibiotics cause reverse tolerance, resulting in reduced efficacy or fewer adverse effects?
What are the indications, dosing regimens, contraindications, and alternative therapies for fluoroquinolones?
What are the age restrictions for quinolone antibiotic use?
Should patients on fluoroquinolone antibiotics be advised to minimize strenuous exercise?
At what age can fluoroquinolones be used in children?
In a 67-year-old woman presenting with altered mental status and suspected psychotropic polypharmacy, what additional laboratory and imaging studies should be obtained to evaluate reversible causes?
Where should an epinephrine auto‑injector be administered in obese adults?
Can vitamin B12 deficiency cause anxiety?
In a patient without legs, where should the 0.3 mg intramuscular epinephrine dose be administered?
I have a cough, fever, periorbital dark circles, eye irritation, and rhinorrhea for four days; what is the likely diagnosis and recommended management?
What is the appropriate intravenous ceftriaxone (Rocephin) dosing and duration for treating a urinary tract infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.